To hear about similar clinical trials, please enter your email below
Trial Title:
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
NCT ID:
NCT06308913
Condition:
Head and Neck Squamous Cell Carcinoma
Conditions: Official terms:
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Pembrolizumab
Conditions: Keywords:
metastatic
Study type:
Interventional
Study phase:
Early Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
INCB081776
Description:
INCB081776 will be given orally on a daily basis. The highest safe/tolerable dose and
schedule will be established by the ongoing phase 1 clinical trial of INCB081776 plus
INCBMGA00012 (NCT03522142), which is 120 mg daily.
Arm group label:
INCB081776/Pembrolizumab and RT for HNSCC
Intervention type:
Drug
Intervention name:
Pembrolizumab
Description:
Immune checkpoint blockade with anti-PD-1 (Pembrolizumab) will be given as 200 mg IV on
cycle 1 day 15 and cycle 1 day 36. Starting from cycle 2, pembrolizumab will be given on
day 1 on each subsequent cycle.
Arm group label:
INCB081776/Pembrolizumab and RT for HNSCC
Intervention type:
Radiation
Intervention name:
Palliative RT
Description:
Palliative RT will be given as either 24 Gy in 3 fractions (8 Gy per fraction) or 20 Gy
in 5 fractions (4 Gy per fraction). The palliative radiation therapy dose will be
determined based on the clinical judgment of the treating radiation oncology physician.
Palliative RT must be completed between cycle 1 day 29 to cycle 1 day 33. After
completion of palliative radiation therapy, patients will continue with additional cycles
of INCB081776 and pembrolizumab until disease progression, intolerance to the combination
regimen, or patient withdrawal.
Arm group label:
INCB081776/Pembrolizumab and RT for HNSCC
Summary:
This study is evaluating INCB081776 when given in combination with the checkpoint
inhibitor pembrolizumab and palliative radiation therapy in patients with metastatic or
recurrent metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). 12
participants will be enrolled and can expect to be on study for up to 12 months.
Detailed description:
Primary Objective
• To evaluate the safety and tolerability of INCB081776 in combination with pembrolizumab
and standard palliative radiation therapy in subjects with recurrent/metastatic squamous
cell carcinoma of the head and neck.
Secondary Objectives
• To determine the preliminary efficacy of INCB081776 in combination with pembrolizumab
plus palliative radiation therapy in subjects with recurrent/metastatic squamous cell
carcinoma of the head and neck. The irradiated lesion (lesion A) will not be included in
the analysis.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Participants must have histologic or cytologic evidence of head and neck squamous
cell carcinoma (HNSCC) that is metastatic or recurrent and therefore considered
incurable. Cutaneous skin squamous cell carcinomas located in the head and neck
region are eligible after discussion with the Sponsor-Investigator.
- Measurable disease that are considered non-amenable to surgery or other curative
treatments or procedures, with at least 1 target lesion available for evaluation.
- The preference is for measurable disease to be selected from a site that has
not received any prior radiation or locoregional therapy. However, if a tumor
lesion is situated in a previously irradiated area, or in an area subjected to
other prior locoregional therapy, the lesion should demonstrate disease
progression after the prior treatment.
- Prior cancer treatment must be completed at least 14 days prior to enrollment (for
chemotherapy, targeted small molecular therapy, or radiation therapy. Prior
treatment with a monoclonal antibody must be completed at least 28 days prior to
enrollment. Participants must have recovered from all reversible acute toxic effects
of the regimen (other than alopecia) to ≤ Grade 1 or baseline.
- Participants must have two "index" tumors that meet the following criteria:
- Index tumor A (lesion to receive palliative radiation therapy):
- is deemed by the treating radiation oncologist to potentially benefit from
palliative radiation
- is at least 1 cm in longest dimension
- Index tumor B (lesion to undergo biopsy):
- Is deemed by the treating physician to be amenable to biopsy
- Is at least 1 cm in longest dimension.
- Participants must be willing to provide at least 2 research biopsies (up
to 3 research biopsies) during the conduct of the study.
- Note: If a subject is scheduled to have a baseline or on-study tumor
biopsy, and the investigator believes that the tumor tissue cannot be
obtained safely, then the biopsy may be omitted with approval by the
Sponsor-Investigator. The participant may be replaced in order to enroll
sufficient number of subjects for biomarker evaluation.
- Note: Care should be taken to biopsy the same lesions for research
samples. The preference is for the same lesion to be biopsied at all time
points. If a lesion is no longer amenable for a research biopsy (for
examples: due to a decrease in size, becomes inaccessible, is not
safe/feasible for a biopsy), then an alternative lesion may be utilized
with approval by the Sponsor-Investigator. Index tumor B (lesion to
undergo biopsy) must not have received palliative radiation therapy during
the study.
- Participants must be willing to provide at least 2 collections of fresh research
biopsies (up to 3 fresh research biopsies) during the conduct of this study.
- Research biopsy #1 (baseline, mandatory). Archival tissue obtained since
completion of last therapy may be used.
- Research biopsy #2 (cycle 1 days 9-14, after treatment with INCB081776 but
prior to pembrolizumab, mandatory)
- Research biopsy #3 (cycle 1 day 37-56, after treatment with INCB081776,
pembrolizumab and palliative RT). For participants who had baseline archival
tissue collected (no baseline research biopsy was obtained), this fresh core
biopsy is mandatory. For participants who underwent a fresh core research
biopsy at baseline, this biopsy is optional.
- Note: If a participant is scheduled to have an on-study tumor biopsy, and the
investigator believes that the tumor tissue cannot be obtained safely, then the
biopsy may be omitted after discussion with the Sponsor-Investigator. The
participant may be replaced in order to enroll sufficient number of subjects
for biomarker evaluation.
- Note: Care should be taken to biopsy the same lesion for the on-treatment
samples
Exclusion Criteria:
- Subjects with significant intercurrent illnesses per physician discretion.
- Subjects with a diagnosed auto-immune disease requiring systemic treatment with
immunosuppressants.
- Subjects with known genetic conditions causing pre-disposition to RT toxicity (i.e:
Li-Fraumeni, ATM deficiency, active scleroderma, etc.).
- Subjects with known retinal or ophthalmologic disorders or conditions. Subjects with
macular degeneration, proliferative diabetic retinopathy or diabetic retinopathy
with macular edema, retinal vein occlusions, uveitis, central serous retinopathy,
leukemic retinopathy, inherited retinal degenerations, known family history of
inherited retinal degenerations, and subjects at risk for angle closure glaucoma
from pupillary dilation are ineligible. Subjects with other clinically significant
abnormalities identified during ophthalmic screening examinations that may confound
ocular monitoring are ineligible.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
UW Carbone Cancer Center
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Start date:
September 18, 2024
Completion date:
August 31, 2027
Lead sponsor:
Agency:
University of Wisconsin, Madison
Agency class:
Other
Collaborator:
Agency:
National Institute of Dental and Craniofacial Research (NIDCR)
Agency class:
NIH
Collaborator:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
University of Wisconsin, Madison
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06308913